Emsam (Selegiline)

Emsam (selegiline transdermal system) is a once-daily skin patch for the treatment of major depressive disorder in adults. It is the only antidepressant MAOI delivered through the skin, which reduces exposure of the gut to the drug.

Selegiline inhibits monoamine oxidase enzymes in the brain, increasing levels of mood-related neurotransmitters such as serotonin, noradrenaline and dopamine. The starting and target dose is 6 mg/24 h, applied to dry, intact skin on the upper torso, thigh or outer upper arm.

• Boxed warning: antidepressants increase the risk of suicidal thoughts and behaviour in children, adolescents and young adults; patients should be monitored closely. Emsam is not for use in children under 12.
• Contraindicated with SSRIs, SNRIs, tricyclic antidepressants, bupropion, tramadol, methadone, meperidine, carbamazepine, oxcarbazepine and other drugs because of the risk of serotonin syndrome or hypertensive crisis.
• At 9 mg/24 h and 12 mg/24 h, foods high in tyramine must be avoided to prevent dangerous rises in blood pressure.
• Application-site reactions and low blood pressure on standing are common; avoid exposing the patch to external heat.

How can a patient in India get Emsam?

Emsam is an imported medicine and is not readily available through regular pharmacies in India. It can still be accessed legally on a named-patient basis, subject to Indian import regulations.

What do I need to provide?

• A valid prescription from a registered psychiatrist
• Psychiatric assessment confirming major depressive disorder
• Patient ID proof issued by the Government of India

Is the order confirmed straight away?

No. We confirm it only once a valid prescription has been received and verified.

Indian Pharma Network (IPN) sources Emsam through its authorised distribution network and arranges supply to patients, doctors and hospitals within the applicable legal framework.

For the current price of Emsam in India and expected delivery time, call +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA-approved in February 2006.

What does Emsam treat?

It is a transdermal monoamine oxidase inhibitor (MAOI), prescribed for major depressive disorder in adults.

Which company makes Emsam?

Mylan Specialty (Viatris).

Do I need a special diet with Emsam?

At the 6 mg/24 h dose no dietary changes are required; at 9 mg/24 h and 12 mg/24 h a tyramine-restricted diet is needed.

What is the mechanism of Emsam?

Selegiline inhibits monoamine oxidase enzymes in the brain, increasing levels of mood-related neurotransmitters such as serotonin, noradrenaline and dopamine.

Does Emsam have FDA approval?

Yes. Emsam is FDA-approved for the treatment of major depressive disorder in adults.